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ARTICLE
Biallelic mutations in valyl-tRNA synthetase gene
VARS are associated with a progressive
neurodevelopmental epileptic encephalopathy
Jennifer Friedman1,2,3,4, Desiree E. Smith5,6, Mahmoud Y. Issa 7, Valentina Stanley1,8, Rengang Wang1,8,
Marisa I. Mendes5,6, Meredith S. Wright4, Kristen Wigby3,4, Amber Hildreth3,4, John R. Crawford1,2,3,
Alanna E. Koehler 8, Shimul Chowdhury4, Shareef Nahas4, Liting Zhai9, Zhiwen Xu9,10, Wing-Sze Lo9,10,
Kiely N. James1,8, Damir Musaev1,8, Andrea Accogli11,12, Kether Guerrero11,13,14, Luan T. Tran11,13,14,
Tarek E.I. Omar15, Tawfeg Ben-Omran16, David Dimmock4, Stephen F. Kingsmore4, Gajja S. Salomons5,6,
Maha S. Zaki7, Geneviève Bernard11,13,14 & Joseph G. Gleeson1,2,3,4,8
Aminoacyl-tRNA synthetases (ARSs) function to transfer amino acids to cognate tRNA
molecules, which are required for protein translation. To date, biallelic mutations in 31 ARS
genes are known to cause recessive, early-onset severe multi-organ diseases. VARS encodes
the only known valine cytoplasmic-localized aminoacyl-tRNA synthetase. Here, we report
seven patients from five unrelated families with five different biallelic missense variants in
VARS. Subjects present with a range of global developmental delay, epileptic encephalopathy
and primary or progressive microcephaly. Longitudinal assessment demonstrates progressive
cortical atrophy and white matter volume loss. Variants map to the VARS tRNA binding
domain and adjacent to the anticodon domain, and disrupt highly conserved residues. Patient
primary cells show intact VARS protein but reduced enzymatic activity, suggesting partial
loss of function. The implication of VARS in pediatric neurodegeneration broadens the
spectrum of human diseases due to mutations in tRNA synthetase genes.
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The spectrum of genes responsible for pediatric neurode-velopmental and neurodegenerative conditions (PNDDC)is extraordinarily broad, often requiring a whole-exome or
whole-genome sequencing approach rather than a targeted gene
or panel approach in order to achieve a molecular diagnosis and
to identify new causes of disease. This is in part due to the vast
number of genetic forms of PNDDC, in addition to wide-ranging
phenotypic and genetic heterogeneity among these conditions.
Previous publications have addressed this issue by recruitment of
large cohorts of patients with PNDDC, or through matchmaker
exchanges to identify recurrently mutated genes1–5.
Charged tRNAs are required by the ribosome to meet the
cellular requirement for protein synthesis, and their availability
regulates many aspects of cellular function6. Charging of tRNAs
requires the function of aminoacyl-tRNA synthetases (ARSs),
which are ubiquitously expressed and highly evolutionarily
conserved. Each amino acid has one or more designated
ARS enzymes to catalyze a bond with a cognate tRNA. With 37
ARS genes for the 20 typical amino acids, 17 encode a
cytoplasmic-localized enzyme, 17 encode a mitochondrial-
localized enzyme, and 3 charge tRNA in both cellular loca-
tions7. Individual ARS proteins that function predominantly in
the mitochondria are designated with a ‘2’ after the gene name,
for instance the VARS paralogue functions in the cytoplasm
and VARS2 paralogue functions in the mitochondria to charge
valine tRNAs.
Mutations in 31 different ARS genes are currently implicated
in recessive diseases, with mutations in most mitochondrial-
localized ARS genes associated with mitochondrial encephalo-
pathies, and cytoplasmic-localized ARS genes associated with
a wider range of diseases but affecting primarily the nervous
system. Analysis of mutant ARS enzyme activity typically
show moderate to severe reduction, but with some activity
remaining8–10, consistent with the idea that these are non-
redundant and essential enzymes.
Valine is an essential branched chain amino acid, utilized for
protein synthesis both in the cytoplasm and mitochondria.
VARS2 is nuclear-encoded and is mutated in individuals with
recessive mitochondrial encephalomyopathy11–13. Missense
mutations in VARS2 found in patients can lead to protein
destabilization, which can reduce steady-state protein levels.
Karaca et al. identified VARS as a candidate gene among 40 other
genes profiled in 128 families with a range of neurologic pre-
sentations. They reported two pathogenic variants NM_006295.2:
c.2653C>T p.(Leu885Phe) and NM_006295.2:c.3173G>A p.
(Arg1058Gln) in two consanguineous families with epileptic
encephalopathy; phenotypic spectrum and function were not
studied3.
Here we expand the findings of Karaca et al. by using exome or
genome sequencing to identify and characterize five distinct bi-
allelic VARS variants in seven additional epileptic encephalopathy
patients. The VARS phenotype is characterized by a spectrum of
global developmental delay, epileptic encephalopathy and pri-
mary or progressive microcephaly. Pathogenic variants disrupt
highly conserved residues, and localize to the VARS tRNA
binding domain and adjacent to the anticodon domain. In
patients for whom tissue was available, fibroblasts show intact
VARS protein but reduced enzymatic activity, suggesting partial
loss of function.
Results
Identification of VARS biallelic mutations in five families.
Patients were referred for neurological or genetic assessment for
PNDDC at the National Research Center in Cairo, Rady Chil-
dren’s Hospital in San Diego, and McGill University Health
Center in Montreal. Seven patients from five families were
included in this study. Whole-exome (WES) or whole-genome
(WGS) sequencing in each family led to the identification of a
single genetic variant that met criteria for causality using estab-
lished protocols14–16. The researchers enrolling subjects from
these three locations were matched through collaborative net-
works and the Matchmaker Exchange1 and recognized a common
core phenotype of neurodevelopmental disorder with micro-
cephaly, seizures, and cortical atrophy (NDMSCA), which con-
tributed to the OMIM entry #617802 linked to VARS. Families
2937, 3308, and 3439, all from Egypt, had documented first-
cousin parental consanguinity. Family 3007, originating from
Syria, had a history of remote parental consanguinity. Family
GB31, from Montreal, Canada, was Caucasian and had no history
of consanguinity (Fig. 1a).
WES was used for analysis of families 2937, 3308, 3439, and
GB31, and focused on identification of homozygous or com-
pound heterozygous, rare (low minor allele frequency in the
gnomAD variome (http://gnomad.broadinstitute.org) and not
identified in the GME variome (http://igm.ucsd.edu/gme/)) and
potentially damaging variants prioritized using the American
College of Medical Genetics organization, OMIM identity, gene
function, protein expression, phenotypic assessment, and in silico
prediction tools. WGS was used for analysis of family 3007 with
analysis filtered to retain variants with allele frequencies of <0.5%
in the Exome Variant Server, 1000 Genomes, and gnomAD
databases and were prioritized using the phenotypes extracted
from the medical record using Human Phenotype Ontology
codes. VAAST and Phevor prioritization algorithms were used to
rank variants (Supplementary Methods 1).
For all families we used standard clinical variant filtering
(Supplementary Methods 1), identifying a group of potentially
pathogenic variants (Supplmentary Data 1). For families 2937,
3308, and 3439, with documented consanguinity, we additionally
filtered for homozygous variants, and further filtered for
segregation within the family, predicted damaging by ‘Mutation
Taster’, and Polyphen2 score >0.85; only the variant in VARS
remained for each family after this approach. For family 3007,
five variants passed filtering for further consideration, and all
except homozygous variants in VARS were discarded due to poor
phenotypic overlap, failure to find a second variant or deletion for
an autosomal recessive condition, or variant inherited from an
unaffected parent in an autosomal dominant condition. For this
family we were unable to fully exclude impact of heteroyzgous
SCO2 stop-gain on clinical phenotype. For family GB1, four
variants met filtering criteria and all except VARS were excluded
based upon failure to find a second variant or deletion for an
autosomal recessive condition or occurrence of variant in a
healthy population. For this family, VARS remained as the final
candidate, and bi-allelic inheritance was confirmed following co-
segregation analysis.
Families 2937, 3308, and 3439, derived from a cohort of 5000
families that underwent WES, and two families recruited from
Cairo, shared the same NM_006295.2:c.3355C>T p.(Arg1119Cys)
variant (Families 3308 and 3439), suggesting a founder mutation
(Table 1, Fig. 1a). One additional family from Cairo (Family
2937) with a similar phenotype had a NM_006295.2:c.2840G>A
p.(Arg947His) variant. Family 3007, identified in San Diego and
of remotely consanguineous Syrian descent, was one of 200
families that were studied with WGS, and had a NM_006295.2:
c.1981C>A p.(Pro661Thr) variant. Family GB31 from Montreal,
Canada had compound heterozygous NM_006295.2:c.
(2074G>C;1324C>T) p.(Ala692Pro;Arg442*) variants. Candidate
variants were confirmed by Sanger sequencing, with segregation
confirmed amongst genetically informative family members
according to a strictly recessive inheritance mode.
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VARS mutations associate with a severe neurodevelopmental
disorder. Family 2937 had a single affected child from an
uncomplicated delivery that developed generalized myoclonic and
focal seizures at 3 months of age. Examination at 1 yr 7 months
showed globally delayed milestones with head circumference of
40 cm (−4.6 SD), axial hypotonia and limb hypertonia, brisk
reflexes and extrapyramidal movements. MRI performed at 1 yr
showed cerebral cortical atrophy and mild central atrophy, with
hypoplastic corpus callosum (Fig. 1b). Feeding difficulties per-
sisted, but seizures had been well controlled on Valproate. Elec-
troencephalogram showed right greater than left epileptiform
discharges.
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Fig. 1 VARSmutations lead to a neurodevelopmental disorder with microcephaly, seizures, and cortical atrophy. a Pedigrees showing consanguinity in three
families (double bars). Family 3007 showed remote consanguinity. Seven affected individuals were identified (black), and one individual was likely affected
but DNA was not available for genotyping (3439-IV-1). Multiple miscarriages in family GB31 suggested fetal demise. b Available axial or midline sagittal
brain MRIs demonstrated diffuse cortical atrophy (yellow star) and thinned corpus callosum (yellow arrow) compared to control. The brain MRI in 3007-II-
1 was acquired at 6 months of age, and thus the patient was probably too young to observe these features. Two individuals from family 3439 had follow-up
MRIs that demonstrated progressive cortical atrophy. D—days; M—months; Y—years. c Major domains of the 1264 amino acid protein, showing the GST,
aminoacylation (including HIGH, Editing and KMSKS domains) and anticodon-binding domains. Disease-associated variants described in this study (red)
and those from Karaca et al.3 (black) are noted. Variants were in the aminoacylation or in or near the anticodon-binding domains, suggesting altered
function. d Sequence conservation of mutated amino acids. The variants were either precisely conserved or maintain charge/polarity, with the exception of
NM_006295.2:c.2653C>T p.(Leu885Phe), which is absent in T. thermophiles
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Family 3308 presented with a single affected child with seizures
beginning at 3 weeks, characterized by generalized myoclonic and
focal seizures on a weekly basis, refractory to treatment with
Valproate and Levetiracetam. Electroencephalogram showed
frequent generalized discharges. Assessment at 6 months showed
severe global developmental delay, head circumference of 36 cm
(−5.2 SD), axial hypotonia and limb hypertonia with brisk
reflexes. There was a ventriculoseptal defect, which was clinically
insignificant. The child died at 3 yr from chronic respiratory
insufficiency resulting from neuromotor disability.
Family 3439 presented with four affected children, all showing
global developmental delay, axial hypotonia, brisk reflexes, and
extrapyramidal movements. The oldest (IV-1) died at 8 months
from seizures and respiratory compromise, but otherwise
followed a nearly identical clinical course. DNA was unavailable
for family members IV-1 and IV-3, and thus molecular diagnosis
could not be confirmed in these individuals. The electroence-
phalogram in 3439-IV-3 showed hypsarrhythmia, and seizures
were refractory to triple therapy with Valproate, Levetiracetam,
and Clonazepam. At last exam, the youngest affected child was
medically fragile but seizures were controlled with Levetiracetam
and Tiagabine. All other affected individuals have now died.
Family 3007 presented with a single affected child at 4 months
with global developmental delay and infantile spasms. Electro-
encephalogram met criteria for hypsarrhythmia. At 10 months
the seizures were controlled on Vigabatrin monotherapy. MRI at
6 months was essentially unremarkable, and head circumference
continued along normal percentiles, but global developmental
delay was evident. This child displayed feeding difficulties and
had persistent mild elevations of liver transaminases (aspartate
aminotransferase and alanine aminotransferase in the low 100s,
without impaired coagulation or gamma-glutamyl transferase
levels). Liver ultrasound demonstrated mildly increased echo-
genicity, not otherwise specified, suggesting mild liver involve-
ment, but follow-up had not demonstrated progression.
Family GB31 presented with a severely affected child soon after
birth (36 weeks gestation). The mother had a history of recurrent
pregnancy loss, including an elective termination at 18 weeks
Table 1 Case phenotype and genotype
2937-III-1 3308-III-1 3439-IV-3 3439-IV-4 3439-IV-5 3007-III-1 GB31-II-6
Proband
Current age 5 yrs F Dec (3 yrs) Dec (8 mos) Dec (10 yrs) 1.5 yrs 10 mos Dec (2.5 mos)
Gender F F M M F F F
Ethnicity Egyptian Egyptian Egyptian Egyptian Egyptian Syrian Caucasian
Consang + + + + + Distant −
Variant
Zygosity Homozygous Homozygous N/A Homozygous Homozygous Homozygous Compound heterozygous
Genomic
(hg19)
chr6:g.31748303C>T chr6:g.31747247G>A N/A chr6:g.31747247G>A chr6:
g.31747247G>A
chr6:g.31750317G>T chr6:g.
(31750138C>G;31753046G>A)
cDNA c.2840G>A c.3355C>T N/A c.3355C>T c.3355C>T c.1981C>A c.(2074G>C; 1324C>T)
Protein p.(Arg947His) p.(Arg1119Cys) N/A p.(Arg1119Cys) p.(Arg1119Cys) p.(Pro661Thr) p.(Ala692Pro;Arg442*)
Perinatal history
Gestation Term Term Term Term Term Term Preterm (36+ 3 wks)
HC at birth
(cm)
33.5 (−0.9 SD) 30 (−3.3 SD) 31.5 (−2 SD) 32.5 (−1.7 SD) 32 (−1.25 SD) 37 (+2.64 SD) 30 (−2.06 SD)
Weight at birth
(kg)
2.53 (−1.7 SD) 2.8 (−1 SD) N/A 3 (−1 SD) 2.8 (−1.3 SD) 3.55 (+0.67 SD) 2.31 (−1.01 SD)
Length at birth
(cm)
46 (−1.6 SD) 47 (−1 SD) N/A 48 (−0.6 SD) 48 (−0.7 SD) 53.3 (+2.25 SD) 41 (−2.64 SD)
Complic – – – – – − oligohyd; IUGR; seizures
Psychomotor development
Gross motor
skills
Delayed Severe delay Severe delay Severe delay Severe delay Delayed Severe delay
Fine motor
skills
Delayed Severe delay Severe delay Ssevere delay Severe delay Delayed N/A
Language Delayed Severe delay Delayed Severe delay Delayed Delayed N/A
Social Delayed Severe delay Severe delay Severe delay Severe delay Delayed N/A
Neurological examination
Age at last
exam
1 yr, 7 mos 6 mos 7 mos 6 yrs 1.5 yrs 10 mos 2 mos
HC (cm) 40 (−4.6 SD) 36 (−5.2 SD) 38.2 (−4 SD) 39 (−8.2 SD) 37.5 (−6.8 SD) 46.2 (+1.4 SD) 30.5 (−6.5 SD)
Weight (kg) 8 (−2.6 SD) 5.5 (−2.1 SD) 5.8 (−2.5 SD) 7.7 (−5.8 SD) 6.5 (−4.4 SD) 9.5 (+0.85 SD) 2.1 (−4.5 SD)
Length (cm) 74 (−2.1 SD) 63 (−0.8 SD) 65 (−1.5 SD) 97 (−3.6 SD) 69 (−3.4 SD) 69.5 (−0.97 SD) 44 (−5.6 SD)
Tone Axial hypotonia limb
hypertonia
axial hypotonia limb
hypertonia
axial hypotonia
limb hypertonia
axial hypotonia, limb
hypertonia
axial hypotonia
limb hypertonia
axial hypotonia axial and limb hypertonia
Reflexes brisk brisk brisk brisk brisk brisk brisk
Extrapyram + + + + + − −
Seizures
Onset 3 mos 3 wks 2 wks 1 wk 40 d 4 mos 2 d
Type Generalized,
myoclonic, focal
Generalized,
myoclonic, focal
Generalized,
myoclonic, focal
Generalized, myoclonic,
focal
Generalized,
myoclonic, focal
Infantile spasms, tonic Multifocal
Frequency Rare Weekly Daily Weekly Daily >10 per day Daily
Control Controlled Refractory Refractory Controlled Controlled Controlled Refractory
Treatments Val Val Lev Val Lev Clon Val Lev Clon Lev Tia Vig Lev Phen Clon Lor
EEG Right frontal
epileptiform
Generalized
discharges
Hypsarrhythmia Generalized focus Generalized
discharges
Hypsarrhythmia Diffuse multifocal epileptiform
Brain MRI
Age of MRI 1 yr 3 yrs 4 mos 3 mos / 4 yrs 4 mos / 18 mos 6 mos 2 d
Findings Cortical atrophy, mild
central atrophy,
hypoplastic CC
Cortical atrophy,
abnormal gyration,
hypoplastic CC
Cortical atrophy,
hypoplastic CC
Progressive central and
cortical atrophy,
hypoplastic CC
Progressive
cortical atrophy,
hypoplastic CC
Normal Severe atrophy and simplified
gyral pattern; abn myelination
hypoplastic CC
Systemic manifestations
Gastrointestinal Feeding difficulties Feeding difficulties,
recurrent vomiting
Feeding
difficulties,
recurrent
vomiting
Feeding difficulties,
recurrent vomiting
Recurrent
vomiting, AST
slight elevation
Feeding difficulties,
elevated AST/ALT, US:
abn liver echo
Feeding difficulties, mild
hepatomegaly
Other VSD PFO, Skeletal survey abn*,
Dysmorphic**
+ present, − absent, d days, mos months, wks weeks, yr(s) years, dec deceased, Consang consanguinity, HC head circumference, SD standard deviations, Complic complications, oligohyd oligohydramnios,
IUGR intrauterine growth restriction, Extrapyram extrapyramidal movements, Val Valproate, Lev Levetiracetam, Clon Clonazepam, Tia Tiagabine, Vig Vigabatrin, Phen Phenobarbital, Lor Lorazepam, CC
corpus callosum, AST aspartate aminotransferase, ALT alanine aminotransferase, US ultrasound, abn abnormal, echo echogenicity, VSD ventriculoseptal defect, PFO patent foramen ovale
*11 ribs bilaterally, suspicion of congenital osteofibrous dysplasia of the right tibia
**Sloping forehead, prominent nasal bridge, apparent hypertelorism, upslanting and short palpebral fissure, large ears and a lumbar hemangioma
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(twins) due to meningomyelocele, a spontaneous termination at
8 weeks, and an elective termination at 14 weeks due to
anencephaly. GB31-II-6 presented at birth with microcephaly,
severe axial hypotonia and appendicular hypertonia, whole body
clonus and seizures. Electroencephalogram demonstrated diffuse
multifocal epileptiform abnormalities. Despite therapy with
Levetiracetam, Phenobarbital, Clonazepam, and Lorazepam,
seizures continued. The child also had facial dysmorphisms
including a sloping forehead, prominent nasal bridge, hypertelor-
ism, upslanting and short palpebral fissure, large ears, and small
lumbar hemangiomas. Skeletal survey showed 11 ribs bilaterally
and congenital osteofibrous dysplasia of the right proximal tibia.
Brain MRI at birth showed severe cortical and cerebellar atrophy
with simplified gyral pattern, delayed myelination, and hypo-
plastic corpus callosum. By 2 months of age, head circumference
was 30.5 cm (−6.5 SD), there was axial and limb hypertonia,
severe feeding difficulties, a clinically significant patent foramen
ovale, and hepatomegaly. Respiratory insufficiency ensued and
the child passed away at 2.5 months of age. Neuropathological
assessment in GB31-II-6 showed brain weight of 169 g (−6 SD)
with simplified gyral pattern, marked reduction in cerebral white
matter volume, absence of cavitation or necrotic lesions, but thin
corpus callosum. The hemispheric white matter was intensely
gliotic with minimal myelination but preserved axonal density,
with a few sudanophilic histiocytes, consistent with a myelination
disorder. Hippocampus, basal ganglia, thalamus, brainstem, and
cerebellum were histologically unremarkable.
VARS deficiency associates with progressive cortical atrophy.
We noted that the head circumference of most affected children
tended to slow in growth by 1 yr of age (Table 1), which predicted
a loss in cerebral growth and/or atrophy. To confirm this suspi-
cion, we repeated brain MRI in older children to assess for
acquired cortical atrophy. Individual 3439-IV-4 had initial brain
MRI at 3 months and then repeated at 4 yr (Fig. 1b). Side-by-side
comparison demonstrated progressive loss of cerebral cortical
volume, with collapse of subcortical white matter volume, evident
on both axial and midline sagittal images. Similarly, individual
3439-IV-5 had an initial brain MRI at 4 months and then repe-
ated at 18 months, demonstrating loss of subcortical white matter
volume and increased lateral ventricle size. The MRI findings
together with brain neuropathology from GB31-II-6 demonstrate
that pathogenic variants in VARS also show particular predilec-
tion for the cerebral white matter.
Mutations in VARS alter evolutionarily conserved amino acids.
The VARS mutations occurred throughout the open reading
frame, predicting alteration in evolutionarily conserved amino
acids. VARS encodes a 1264 amino acid protein consisting of an
N-terminal glutathione-S-transferase and aminoacylation enzy-
matic domains and a C-terminal anticodon-binding domain, used
for recognition of valine tRNAs (Fig. 1c). The amino acids that we
identified as mutated in our cohort, as well as one of the
pathogenic variants identified by Karaca et al.3 were conserved in
all mammals and were further conserved to within the same
amino acid type in all species profiled. Furthermore, all of our
patients had variants that altered amino acid charge or group
(Fig. 1d). The NM_006295.2:c.2653C>T p.(Leu885Phe) Karaca
et al. mutation, however, had no counterpart in T. thermophiles.
Variants predicted to affect protein structure or function. The
class Ia ARS enzymes, which include VARS, utilize an alpha-helix
bundle domain to recognize the key residues in the anticodon
domain of the cognate tRNA, essential for correct charging17. The
structure of the VARS orthologue has been determined in the
tRNA-bound state for T. thermophiles18, where tRNA residues
A35-C36 (the major identity elements), are base-stacked upon
each other, and fit into a pocket on the alpha-helix bundle
domain of VARS. Hydrogen bonds are formed between VARS
and A35-C36 of tRNAVal in a base-specific manner. The dis-
crimination of valine from the structurally similar isoleucine and
threonine in the amino acid binding domain occurs via ‘double
sieve’ mechanisms19, whereby VARS excludes these incorrect
bases using distinct mechanisms.
To predict the impact of the mutations on protein structure, we
utilized a crystal structure of the T. thermophiles VARS-tRNAVal
complex because human and T. thermophilies protein sequences
share high sequence similarity (~90% conservation)18,19, and it is
the only species where structure is available. We constructed a
model of human VARS-tRNAVal complex by homology modeling
and examined the location relative the alpha-helical and beta-
sheets of the protein (Supplementary Fig. 1), as well as how each
mutation is predicted to impact local structure and tRNA binding
(Fig. 2a). Residues Pro661, Arg947, and Arg1119 are in proximity
to the tRNA molecule (<6 Å). The p.(Pro661Thr) mutant exhibits
no obvious change in distance from tRNA or in contacts with
adjacent amino acids, but occurs within a conserved beta-sheet.
Both Arg947 and Arg1119 are in alpha helices and in close
proximity to the C-37 and C-39 of the tRNAVal, respectively.
These may create hydrogen-bonding interactions that would be
abolished by the mutations, possibly leading to reduced tRNA
binding (Figs 2b, d, f). Arg947 in particular has been previously
hypothesized to be important in tRNA binding18.
The other two residues, Ala692 and Arg1058, have a distance
of >15 Å from the tRNA, but again occur in alpha helices. The
NM_006295.2:c.2074G>C p.(Ala692Pro) introduces the helix
breaker proline and is predicted to result in a loss of a hydrogen
bond with Ala689 (Fig. 2c), which may cause a conformational
change, while the NM_006295.2:c.3173G>A p.(Arg1058Gln)
mutation effect is less certain (Fig. 2e). Thus, all patient mutations
that we identified occur within highly ordered regions of VARS,
and some were additionally predicted to have an impact on tRNA
binding or protein structure, possibly affecting the VARS
function.
Patient mutations in VARS reduce aminoacylation activity. To
evaluate the impact of variants on protein stability and function,
we collected skin punches then generated primary fibroblast
cultures from an affected member of four of the families, as well
as parental healthy controls (obligate carriers) in three families,
and compared with results from cultures from unrelated healthy
controls. We observed that cells from affected individuals dis-
played typical growth characteristics under basal conditions. For
some of the recessive ARS genes mutated in human disease, there
are reduced levels of protein at steady state, including for the
mitochondrial-localized VARS213,20–23. However, western blot
analysis demonstrated VARS protein levels in patient cells that
were indistinguishable from controls (Fig. 3a), suggesting that
these mutations do not destabilize VARS or alter steady-state
levels in detectable ways.
VARS transferase activity was assessed by incubating cyto-
plasmic extracts with yeast total tRNA, ATP and [15N]-valine.
Valine bound by tRNA was subsequently quantified by LC-MS/
MS. LARS (leucine) and RARS (arginine) activities were assessed
simultaneously as controls. Extracts from affected individuals
(2937-III-1, 3308-III-1, 3439-IV-4, GB31-II-6) showed that
VARS transferase activity was reduced by about fivefold (i.e., to
20% of levels observed in controls, Fig. 3b) which proved to be
statistically significant (P < 0.0001 for both comparisons, one
tailed Student’s t-test). This reduced but not abolished activity is
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consistent with reduced activity seen in other recessive ARS
diseases. Next we determined if healthy parents showed reduced
activity, given that they are carriers (i.e., heterozygous) for the
mutation. We found that parents had activities that ranged in the
60–80% of unrelated control levels (Fig. 3c), which is consistent
with their heterozygous state. Controls all showed activities
within 10% of each other. Activities of LARS and RARS in
patients showed some variability in activity but were all within
75–110% of control activities. These experiments point to a
specific reduction in VARS activity in patient cells, which likely
accounts for their clinical presentations.
Discussion
The process of charging tRNAs with amino acids is an evolu-
tionarily conserved process in all metazoa, critical for protein
translation. In mammals there are 37 ARS proteins linking the 20
primary amino acids with the 497 human tRNAs. In this study,
we identified seven patients from five families with biallelic
mutations in VARS. There were five pathogenic variants in total,
with three of these present in a homozygous state, while two were
seen in a compound heterozygous state, which associated with the
most clinically severe case. All missense variants were absent or
reported only rarely in public references databases (EXAC, gno-
mAD), predicted pathogenic by in silico analysis, disrupted highly
conserved amino acid residues in critical regions of the protein,
and led to severely reduced transferase activity in the tested
patient cells.
The five distinct VARS pathogenic variants reported here and
two previously identified3 were distributed throughout the VARS
protein. All variants were encompassed in the full-length tran-
script subserving tRNA synthetase activity. Five were located in
the aminoacylation domain, and two were in or adjacent to the
anticodon-binding domain. Interestingly, irrespective of where
the mutation occurred, we found reduced aminoacylation activity,
suggesting that transferase activity reflects both the ability to bind
tRNA as well as transfer the charged valine to the tRNA.
Recent attention has focused on non-translational function of
ARS proteins, evidenced by the addition of newly evolved
domains that are neither necessary nor sufficient for ARS activ-
ity24. For the most part, the function of these additional protein
domains, some of which are mammalian-specific, remain
unknown. The mammalian-specific VARS N-terminal 218 resi-
due GST domain is not essential for ARS activity25, but rather
binds the elongation factor EF-1α to facilitate association and
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abolished contacts with Ala689 and disrupted helical structure. d Residue
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efficient transfer of charged tRNAs26. In addition, there are at
least six alternatively spliced VARS transcripts, which are catalytic
nulls, but display specific biological activities across a spectrum of
cell-based assays, particularly ‘neutrophil oxidative burst’27.
Whether any of the mutations we identified additionally interfere
with non-catalytic functions of VARS will require further study.
Mutations in both mitochondrial and cytoplasmic-localized
ARSs cause a spectrum of recessive disorders, many of which
include neurological phenotypes. Pathogenic variants in cyto-
plasmic ARSs have been associated with microcephaly, seizures,
developmental delay, intellectual disability, and sensorineural
hearing loss28. RARS, DARS, and EPRS bi-allelic mutations cause
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hypomyelination29–31, SARS mutations are implicated in intel-
lectual disability32, and HARS has been associated with Usher
syndrome33. Dominant (mono-allelic) mutations in multiple
ARSs genes (GARS, YARS, AARS, and HARS) have been asso-
ciated with the progressive axonal neuropathy Charcot Marie
Tooth type 2 Disease33–38, presumably acting in a dominant-
negative capacity. In addition to neurologic phenotypes, other
systemic manifestations are associated with recessive cytoplasmic
ARSs mutations (LARS, MARS), including liver dysfunction and
interstitial lung disease39,40. The mechanism driving tissue-
specific phenotypes associated with certain ARS genes remains
largely unexplored.
The non-syndromic clinical presentation of these affected
individuals prevented us from identifying them as the same
genetic condition prior to WES or WGS, but in retrospect several
clinical aspects are shared. The clinical presentation in the first
weeks to months of life with severe epilepsy despite aggressive
anticonvulsant treatment, and association with hypsarrhythmia
on electroencephalogram can be a clue. Another clue is acquired
microcephaly, in the range of minus 5 SDs, observed in all but
one subjects after 6 months of age. The brain MRI appearance of
cortical atrophy with reduced white matter volume without
edema, and without involvement of deep brain structures or
brainstem volume loss can differentiate VARS from leukody-
strophies, mitochondrial, and pontocerebellar disorders. Unfor-
tunately, none of our subjects have yet survived past childhood,
and most succumb from medical complications in the first few
years of life, suggesting a lethal condition.
The clinical features of neurodevelopmental delay with
microcephaly, seizures, and cortical atrophy (MIM#617802)
linked with VARS mutations can be compared with other defined
conditions, as well as the function of the genes implicated in these
disorders. Recessive microcephaly, seizures, and developmental
delay (MCSZ MIM#613402) due to mutations in the DNA-repair
enzyme encoded by PNKP has onset in infancy. Recessive
microcephaly (postnatal progressive) with seizures and brain
atrophy (MIM#613668) is due to mutations in MED17, encoding
a subunit of the transcription pre-initiation mediator complex.
The VARS phenotype is also similar to AIMP1 related disorders
(MIM# 603605) which present with microcephaly, cortical cere-
bral atrophy and early-onset seizures but can be differentiated
from VARS based upon presence of hypomyelinating leukody-
strophy, similar to that of X-linked Pelizaeus–Merzbacher
disease41,42. While there are over 55 unique genetic causes for
early infantile epileptic encephalopathy (EIEE), many involving
neuronal ion channels, we think that the VARS-related syndrome
can be distinguished clinically from EIEE.
The etiology of varied features and severity in our cohort are
uncertain. These may include environmental factors, although the
contribution of other rare variants identified in these patients cannot
be excluded at this point. Multiple miscarriages occurring in family
GB31 that included two different neural tube defects suggests that
the phenotypic spectrum may be even broader, and, at the extreme
end, incompatible with life. Unfortunately, the deceased fetuses were
not available for genotyping, so it remains unproven if they shared
the same genetic mutations. Notably this family displayed the only
protein-termination variant in our cohort, which not surprisingly
may have a more severe impact on protein function.
There is emerging evidence that genes encoding factors
involved in RNA metabolism including tRNA synthetase, tRNA
splicing complex, and RNA helicases43–46, play essential roles in
human brain development. Further study including in vitro and
in vivo modeling systems will be necessary to determine the
mechanism by which pathologic VARS variants disrupt tRNA
synthetase activity, whether alternatively splice transcripts have a
role in neural development or function, how these abnormalities
disrupt normal brain development and how these VARS func-
tions may be related to the function of other genes implicated in
neural development.
Methods
Patient ascertainment. All experiments involving human participants or data
were conducted in compliance with all relevant ethical regulations. Informed
consent was obtained from all participants and their families. Approval for human
subjects research was obtained from National Research Center in Cairo and
University of California, San Diego Institutional Review Boards, the McGill Uni-
versity Health Center Reasearch Institute Research Ethics Board, and Rady Chil-
dren’s Hospital Research Compliance. All affected individuals were clinically
evaluated by a pediatric neurologist and geneticist. Subjects underwent complete
dysmorphological, neurological, and general examinations. Brain MRI was
obtained in all living subjects, and longitudinal assessment was performed up until
the present time to determine disease course. Venous blood or saliva for DNA
isolation was collected from all genetically informative living members of each
family at the time of ascertainment. In four families, dermal skin punch was
obtained after consent from the index individual and genetically informative
relatives, and cultured in 10% fetal bovine serum and DMEM to obtain low-passage
primary fibroblast cultures.
Whole exome or genome sequencing and variant identification. Details
regarding sequencing, filtering and prioritization protocols for each family are
outlined in Supplementary Note 1 and Supplementary Data 1. Exome or Genome
sequencing was performed on affected member(s) from each family using estab-
lished methods16,47,48. All variants were prioritized by allele frequency, conserva-
tion, and predicted effect on protein function, and were tested by Sanger
sequencing for segregation with disease within the entire family.
Construction of human VARS-tRNAVal structural model. The human VARS
structure model was generated by the protein structure homology-modeling server
Phyre V2.049 based on the T. thermophiles VARS structure (PDB: 1GAX). The
structure of T. thermophiles tRNAVal molecule (PDB: 1GAX) was docked into the
human VARS model using the PathDock server50. All the structural figures were
prepared with Pymol (http://www.pymol.org).
Western blot. Western blots were performed with rabbit polyclonal anti-VARS
antibody (Abclonal A4182; 1:1000) and mouse monoclonal anti-a-tubulin (Sigma
T6074; 0.2 μg/ml) in 5% non-fat milk in PBST. Full blot in Supplementary Fig. 2.
Combined VARS, LARS, and RARS activity assay. Skin punches were collected
at a single timepoint from each patient studied here, then expanded and used for
enzymatic analysis. Steady-state aminoacylation assays were performed in technical
triplicate in fibroblast lysates [cytosolic fraction, no mitochondrial proteins were
detected using western blot (Supplementary Fig. 3)] at 37 °C for 10min in reaction
buffer (50mmol/L Tris buffer pH 7.5, 12mmol/L MgCl2, 25 mmol/L KCl, 1 mg/mL
bovine serum albumin, 0.5 mmol/L spermine, 1 mmol/L ATP, 0.2 mmol/L yeast
total tRNA, 1 mmol/L dithiotreitol, 0.3 mmol/L [15N]-valine, [13C2]-leucine and
[15N2]-arginine). Reaction was terminated using trichloroacetic acid. After sample
washing with trichloroacetic acid, ammonia was added to release the labeled amino
acids from the tRNAs. [13C]-valine, [D3]-leucine, and [13C6]-arginine were added as
internal standards. Labeled amino acids were quantified by LC-MS/MS. Intra-assay
variation was <15%. Student t-test with unequal variances were performed using
SPSS version 22 to test significant differences between patients and controls/carriers.
Data availability
VARS variant data that support the findings of this study have been deposited in
ClinVar with accession codes [https://www.ncbi.nlm.nih.gov/clinvar/variation/
522588/#clinical-assertions] SCV000715349.1 (family 3007), SCV000734850
(c.2074G>C), and SCV000734851 (c.1324C>T) (family GB31). The whole-exome
sequencing data from individuals from families 2937, 3308, and 3439 in this study
have been deposited in the database of Genotypes and Phenotypes (dbGaP) under
accession phs000288.v1.p1. Additional data that support the findings of this study
are available from the corresponding author upon reasonable request.
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